CBIO (Crescent Biopharma) Beta: N/A (As of Jun. 27, 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.56
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Crescent Biopharma's Beta is Not available.

Crescent Biopharma  (NAS:CBIO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Crescent Biopharma Beta Related Terms

Crescent Biopharma Beta Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Beta Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Beta
0.00 0.00

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
CBIO
10GF Score
Crescent Biopharma Inc CBIO
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price